These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 18595699

  • 1. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.
    Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS.
    Breast; 2008 Dec; 17(6):646-53. PubMed ID: 18595699
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 3. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF.
    Jpn J Clin Oncol; 2005 Sep 12; 35(9):514-9. PubMed ID: 16199422
    [Abstract] [Full Text] [Related]

  • 4. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.
    Stemmer SM, Rizel S, Hardan I, Adamo A, Neumann A, Goffman J, Brenner HJ, Pfeffer MR.
    J Clin Oncol; 2003 Jul 15; 21(14):2713-8. PubMed ID: 12860949
    [Abstract] [Full Text] [Related]

  • 5. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y, Xu BH, Li Q, Zhang P, Zhao LM, Yuan P, Wang JY.
    Zhonghua Yi Xue Za Zhi; 2008 Jan 08; 88(2):77-81. PubMed ID: 18353207
    [Abstract] [Full Text] [Related]

  • 6. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I, Yildiz F, Ozyigit G, Sari S, Gurkaynak M, Selek U, Hayran M.
    Acta Oncol; 2008 Jan 08; 47(2):232-8. PubMed ID: 17924207
    [Abstract] [Full Text] [Related]

  • 7. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer.
    Lohrisch C, Paltiel C, Gelmon K, Speers C, Taylor S, Barnett J, Olivotto IA.
    J Clin Oncol; 2006 Oct 20; 24(30):4888-94. PubMed ID: 17015884
    [Abstract] [Full Text] [Related]

  • 8. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B, Camlibel M, Dinc S, Gulcelik MA, Atalay C, Alagol H.
    J Exp Clin Cancer Res; 2005 Sep 20; 24(3):363-72. PubMed ID: 16270522
    [Abstract] [Full Text] [Related]

  • 9. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    Breast Cancer Res Treat; 2009 Jul 20; 116(1):153-60. PubMed ID: 18787948
    [Abstract] [Full Text] [Related]

  • 10. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy.
    Dinshaw KA, Budrukkar AN, Chinoy RF, Sarin R, Badwe R, Hawaldar R, Shrivastava SK.
    Int J Radiat Oncol Biol Phys; 2005 Nov 15; 63(4):1132-41. PubMed ID: 15978744
    [Abstract] [Full Text] [Related]

  • 11. Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
    Jara Sánchez C, Ruiz A, Martín M, Antón A, Munárriz B, Plazaola A, Schneider J, Martínez del Prado P, Alba E, Fernández-Aramburo A.
    Breast Cancer Res Treat; 2007 Jan 15; 101(2):215-23. PubMed ID: 16823507
    [Abstract] [Full Text] [Related]

  • 12. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F, Carpano S, Sergi D, Di Lauro L, Amodio A, Vici P, Abbate MI, Ferranti FR, Viola G, Botti C, Foggi P, Sperduti I, Lopez M.
    Clin Ter; 2007 Jan 15; 158(4):331-41. PubMed ID: 17953285
    [Abstract] [Full Text] [Related]

  • 13. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.
    Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H, Chollet P.
    Breast Cancer Res Treat; 2005 Dec 15; 94(3):255-63. PubMed ID: 16267618
    [Abstract] [Full Text] [Related]

  • 14. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
    Huang CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin CH, Lu YS, Chang KJ.
    Oncologist; 2008 Jul 15; 13(7):751-60. PubMed ID: 18614591
    [Abstract] [Full Text] [Related]

  • 15. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, Stackhouse C, Wilkins L, Evans I, Berry P, Rimmer K, Tucker E.
    Cytometry B Clin Cytom; 2004 May 15; 59(1):24-31. PubMed ID: 15108167
    [Abstract] [Full Text] [Related]

  • 16. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
    Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S.
    J Clin Oncol; 2007 Feb 20; 25(6):656-61. PubMed ID: 17308269
    [Abstract] [Full Text] [Related]

  • 17. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome.
    Geara FB, Nasr E, Tucker SL, Charafeddine M, Dabaja B, Eid T, Abbas J, Salem Z, Shamseddine A, Issa P, El Saghir N.
    Int J Radiat Oncol Biol Phys; 2007 Jun 01; 68(2):364-9. PubMed ID: 17324529
    [Abstract] [Full Text] [Related]

  • 18. Effects of quality of treatment on prognosis in primary breast cancer patients treated in daily practice.
    Ottevanger PB, De Mulder PH, Grol RP, Van Lier H, Beex LV.
    Anticancer Res; 2002 Jun 01; 22(1A):459-65. PubMed ID: 12017333
    [Abstract] [Full Text] [Related]

  • 19. [Long-term results of preoperative chemotherapy for operable breast cancer].
    Zhang B, Cai Y, Zhang Q.
    Zhonghua Zhong Liu Za Zhi; 1997 Jul 01; 19(4):277-80. PubMed ID: 11038758
    [Abstract] [Full Text] [Related]

  • 20. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2008 Apr 01; 14(7):2082-7. PubMed ID: 18381948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.